Is Kite Pharma (KITE) Stock a Sell after Cynthia Butitta’s Insider Sale?; Zix (ZIXI) Sentiment Is 1.06

June 13, 2017 - By Nellie Frank

Zix Corporation offers e-mail encryption, data loss prevention and bring-your-own-device security to meet business data protection and compliance needs. The company has market cap of $357.27 million. The Firm operates through e-mail encryption and security solutions. It has a 58.59 P/E ratio. The Company’s Zix Email Encryption enables the secure exchange of e-mails that include sensitive information through a secure messaging service.

At average stock price per share of $88.5, Cynthia Butitta, the Kite Pharma Inc’s Chief Operating Officer unloaded 10,000 shares of Kite Pharma Inc worth $885,491 U.S. Dollars. The probability of this trade remaining a secret is very little, with the Chief Operating Officer currently possessing 117,795 shares — that is 0.21% of the total market capitalization of the company. This deal was conducted on 12/06/2017. A legal form filed with the Security and Exchange Commission and free at your disposal for review here, gives extra info for the deal.

Analysts await Zix Corporation (NASDAQ:ZIXI) to report earnings on July, 25. They expect $0.03 EPS, down 25.00% or $0.01 from last year’s $0.04 per share. ZIXI’s profit will be $1.62M for 55.08 P/E if the $0.03 EPS becomes a reality. After $0.03 actual EPS reported by Zix Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Since January 1, 0001, it had 0 buys, and 9 insider sales for $2.74 million activity.

The stock increased 5.59% or $0.35 during the last trading session, reaching $6.61. About shares traded. Zix Corporation (ZIXI) has risen 57.30% since June 13, 2016 and is uptrending. It has outperformed by 40.60% the S&P500.

Perkins Capital Management Inc holds 1.52% of its portfolio in Zix Corporation for 280,989 shares. Perritt Capital Management Inc owns 1.02 million shares or 1.22% of their US portfolio. Moreover, Kestrel Investment Management Corp has 0.94% invested in the company for 509,450 shares. The Connecticut-based Thomson Horstmann & Bryant Inc has invested 0.75% in the stock. Connors Investor Services Inc, a Pennsylvania-based fund reported 632,122 shares.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $4.91 billion. The Firm is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. It currently has negative earnings. The Firm offers engineered autologous cell therapy, which is an approach to the treatment of cancer.

Since December 20, 2016, it had 5 insider purchases, and 24 sales for $18.01 million activity. $776,746 worth of Kite Pharma Inc (NASDAQ:KITE) shares were sold by BUTITTA CYNTHIA M. Shares for $250,427 were bought by JENKINSON PAUL L. Wiezorek Jeffrey sold $1.35 million worth of stock. Another trade for 18,800 shares valued at $1.40 million was made by DOUMANI ROY on Wednesday, March 1. $3.41M worth of Kite Pharma Inc (NASDAQ:KITE) was sold by Kim Helen Susan on Tuesday, February 28. On Tuesday, December 20 the insider Chang David D sold $90,938. On Tuesday, May 9 Nussbaum Ran bought $679,474 worth of Kite Pharma Inc (NASDAQ:KITE) or 9,832 shares.

Investors sentiment decreased to 1.31 in 2016 Q4. Its down 0.32, from 1.63 in 2016Q3. It turned negative, as 34 investors sold Kite Pharma Inc shares while 43 reduced holdings. 30 funds opened positions while 71 raised stakes. 43.05 million shares or 17.06% more from 36.77 million shares in 2016Q3 were reported. Jpmorgan Chase & Company stated it has 0.03% in Kite Pharma Inc (NASDAQ:KITE). New York-based Hudson Bay Limited Partnership has invested 0.12% in Kite Pharma Inc (NASDAQ:KITE). Wildcat Capital Ltd Co has invested 48.63% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). Glg Limited holds 0.1% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 30,702 shares. Sphera Funds Mngmt Limited invested 0.57% in Kite Pharma Inc (NASDAQ:KITE). Raymond James Assocs owns 12,279 shares for 0% of their portfolio. Deerfield Management Company owns 0.55% invested in Kite Pharma Inc (NASDAQ:KITE) for 297,902 shares. Rock Springs Management L P holds 0.24% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 79,000 shares. Credit Suisse Ag accumulated 96,198 shares or 0% of the stock. Rice Hall James & Ltd Liability Company invested in 0.1% or 45,402 shares. Pnc Gru owns 0% invested in Kite Pharma Inc (NASDAQ:KITE) for 200 shares. Moreover, Solaris Asset Ltd Limited Liability Company has 0.02% invested in Kite Pharma Inc (NASDAQ:KITE). Cg Asset Ltd Liability Com reported 21,625 shares. Cim Inv Mangement holds 0.1% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 6,400 shares. Td Asset Inc stated it has 0% in Kite Pharma Inc (NASDAQ:KITE).

Among 16 analysts covering Kite Pharma (NASDAQ:KITE), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 69% are positive. Kite Pharma has $100 highest and $46 lowest target. $78.35’s average target is -8.66% below currents $85.78 stock price. Kite Pharma had 35 analyst reports since August 4, 2015 according to SRatingsIntel. Standpoint Research downgraded the shares of KITE in report on Friday, November 13 to “Hold” rating. Stifel Nicolaus maintained Kite Pharma Inc (NASDAQ:KITE) on Sunday, August 16 with “Buy” rating. On Monday, March 13 the stock rating was downgraded by Standpoint Research to “Hold”. Wedbush initiated Kite Pharma Inc (NASDAQ:KITE) rating on Thursday, February 2. Wedbush has “Neutral” rating and $46 target. Canaccord Genuity maintained it with “Buy” rating and $90 target in Friday, August 14 report. The rating was initiated by Roth Capital on Wednesday, January 4 with “Buy”. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Equal-Weight” rating given on Wednesday, July 6 by Barclays Capital. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Mkt Perform” rating given on Tuesday, December 8 by FBR Capital. As per Friday, August 14, the company rating was maintained by Guggenheim. Mizuho maintained Kite Pharma Inc (NASDAQ:KITE) rating on Monday, August 17. Mizuho has “Outperform” rating and $90 target.

The stock decreased 2.29% or $2.01 during the last trading session, reaching $85.78. About shares traded. Kite Pharma Inc (NASDAQ:KITE) has risen 55.47% since June 13, 2016 and is uptrending. It has outperformed by 38.77% the S&P500.